Invion

Subscribe to receive announcements and updates from Invion.

New investors

Home

Announcements

Updates

Lato

Invion has received a number of enquirers from shareholders and we believe several of these questions will be of interest to all investors. In an effort to promote investor engagement and a deeper understanding of Invion, we have compiled the following FAQs and responses.

We will continue to update this list, so encourage shareholders to continue submitting their questions to us at investor@inviongroup.com.

1. When will the share consolidation be completed?

As per the timetable put on the ASX for the ongoing share consolidation (please refer to announcement lodged on 16 October 2024), the Company’s share registry will issue updated holding statements to all shareholders and this will be reflected on the registry platform and ASX by 28 November 2024.

As in the letter sent to shareholders on 22 November 2024, all Invion shareholders will have every 100 shares and 100 options converted to 1 share and 1 option respectively with fractions of a share and option being rounded up to the nearest whole number.

The timetable for all this is also mentioned on the Explanatory Memorandum of the Notice of Meeting which every Invion shareholder would have received for the AGM and is on the ASX previously (please refer to announcement lodged on 15 October 2024).

We recommend Shareholders to refer to pages 16 and 17 of the Notice of Meeting.  This is taken as read and accepted as this was approved by shareholders at last week’s AGM.

The Company’s ASX ticker will revert back to ‘IVX’ upon completion of the consolidation.

2. Why have my shares in Invion disappeared?

As per the timetable put on the ASX for the ongoing share consolidation the 20th of November is the date of deferred settlement for Invion shares with normal trading to commence and be sorted by Thursday 28th November. In the meantime, Invion's shares are trading under the ticker "IVXDB".

From that day onwards, this should be reflected correctly and then trading and appearing as normal. All Invion shareholders will have every 100 shares and 100 options converted to 1 share and 1 option respectively with fractions of a share and option being rounded up to the nearest whole number. 

All shareholders will receive a letter explaining the share consolidation and their amended holding statement. The timetable for all this is also mentioned on the Explanatory Memorandum of the NOM, which every Invion shareholder would have received for the AGM and is on the ASX previously.

3. Will existing shareholders be disadvantaged by the 100:1 share consolidation?

No, existing shareholders will not be disadvantaged by the 100:1 share consolidation. Share consolidations do not affect the total value of shareholders' holdings. For example, 100 shares valued at $0.002 each will be consolidated into 1 share valued at $0.20, keeping the overall value unchanged.

The purpose of the consolidation is to reduce exaggerated percentage movements in the stock price, which can make it difficult for investors to take significant positions due to large fluctuations in the mark-to-market value of their investments. Additionally, the consolidation is intended to attract more sophisticated and long-term investors, many of whom have shown strong support for this decision.

4. What is Invion’s go-to-market strategy and revenue projections?

As a biotech company, Invion’s revenue generating process is a long-term journey, as it often takes years for new treatments to receive approval for sale.

However, many biotech companies, including Invion, aim to license or sell their technology to pharmaceutical companies before generating revenue. Invion's focus is on creating significant value inflection points, such as positive clinical trial results, which validate the technology and make it attractive for partnerships or mergers and acquisitions.

Currently, Invion is working on several developments:

For prostate cancer, the first clinical trial has been completed.

The skin cancer trial has been approved and is now in the screening and recruitment stage.

An anogenital cancer trial is in progress in collaboration with Peter Mac, leveraging an orphan drug designation for a faster regulatory pathway.

To balance its limited resources, Invion uses two approaches:

Independent development of programs with high impact and low cost, such as the skin cancer and anogenital cancer trials.

Collaborative development with external partners, such as Dr.inB for HPV trials and Hanlim Pharma for glioblastoma trials, both of whom also provide funding support.

5. What are the next steps for the prostate cancer study following the Phase 2 trial results?

The Phase 2 trial results for prostate cancer were very promising, demonstrating that the treatment is safe and achieved an efficacy response rate of 40% or higher. However, significantly larger and more expensive trials will be needed to advance the prostate program further. Invion is open to exploring partnerships to support these next steps, which is a common strategy in the biotech industry.

The Company has been engaging with potential partners both domestically and internationally to secure collaborations. Invion has already partnered with Hanlim Pharma and Dr.inB, who are supporting trials for glioblastoma (a deadly form of brain cancer) and human papillomavirus (HPV), respectively.

The positive results from the prostate cancer trial also increase confidence in the success of the ongoing skin cancer trial, as the safety data for INV043 was highly favourable. This reinforces the belief that a topical ointment for superficial skin cancers will be safe, allowing the focus to shift toward optimising the regimen for maximum efficacy.

6. How is Invion addressing the slow share price performance despite positive news flow?

Invion has made several positive announcements over the past 12 months, including the Peter Mac combination study, which improved immunotherapy response rates from 12% to 80%; the HPV proof-of-concept trial funded by Dr.inB; preclinical glioblastoma studies funded by Hanlim Pharma; Phase 2 results for the prostate cancer trial; and the approval and commencement of screening for the Phase 1/2 non-melanoma skin cancer trial.

Invion’s share price has yet to reflect these successes. While the Company cannot control the share price, it believes the issue may lie in technical factors and limited investor awareness. To address the technical issue, Invion has implemented a share consolidation to move away from a sub-penny stock price.

To improve awareness, Invion is actively engaging with investors through one-on-one sessions, presentations at key industry events, and increased outreach both domestically and internationally.

The company acknowledges that building sustainable investor engagement will take time, but this process has already begun. Additionally, Invion anticipates making several significant announcements over the next 12 months to further drive interest and momentum in the market.

Frequently Asked Questions (FAQs)